At Copernicus, we think outside the virus, utilizing our proprietary compacted nanoparticle delivery system to treat diseases without all of the drawbacks of AAV therapies.
For Better Lives.
The Gene Therapy Revolution Has Begun.
The first human genome cost nearly $3 billion; today a whole genome costs only $1,000.
Over a decade since the Human Genome Project, we are now beginning to finally realize the true potential of a greater understanding of human genetics and disease.
With a wealth of new genetic information being generated each day, gene therapy and precision medicine will drive pharmaceuticals in the 21st century and beyond.
At Copernicus, we are committed to driving this revolution forward in order to improve lives across the globe.
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company with a specific focus on utilizing gene therapy to treat diseases with high unmet need.
We are a diverse team of doctors, scientists, and patient advocates committed to using our knowledge and experience to create novel therapies that improve lives.
Founded on technologies developed at Case Western Reserve University in Cleveland, Ohio, we have a strong connection to the growing biotechnology industry in Northeast Ohio.